title: Oncofetal fibronectin mRNA is highly abundant in the blood of patients with papillary thyroid carcinoma and correlates with high-serum thyroid-stimulating hormone levels.
abstract: BACKGROUND
  Papillary thyroid carcinoma (PTC) cells express oncofetal fibronectin (onfFN) mRNA, which may be useful to detect circulating tumor cells. The objective of this study was to determine the fraction of PTC patients having onfFN mRNA in their peripheral blood and to determine if onfFN mRNA levels are correlated with the status of the disease or with thyroid-stimulating hormone (TSH) serum concentrations.
  
  
  METHODS
  This study included 95 PTC patients, who were previously treated by thyroidectomy and radioactive iodine administration. Patients were examined by cervical sonography, whole-body (131)I scintigraphy, thyroglobulin measurement, and onfFN mRNA quantification both when they were being treated with L-thyroxine (L-T4) and after L-T4 withdrawal. The mean value for onfFN mRNA in blood from 25 healthy subjects was used as control for the onfFN mRNA assay.
  
  
  RESULTS
  After L-T4 withdrawal, serum TSH levels rose and onfFN mRNA was found in the peripheral blood of 33 of 64 (52%) disease-free patients, 15 of 23 (65%) patients with local residual disease, and 6 of 8 (75%) patients with known local or distant metastases. Continuous administration of L-T4 repressed serum TSH. In this state none of 17 (0%) disease-free patients and 1 of 4 (25%) patients with local residual disease had an elevated onfFN mRNA level, and 2 of 4 (50%) patients with metastasis had positive tests for serum onfFN mRNA.
  
  
  CONCLUSIONS
  onfFN transcripts are highly abundant in the peripheral blood of patients with PTC. L-T4 withdrawal, which produced elevated serum TSH concentrations in these athyroidic patients, markedly increased the fraction with positive tests for serum onfFN mRNA at all stages of the disease. Analyzing onfFN mRNA in the absence of a TSH stimulus allows a much better discrimination of different states of PTC disease and, based on current concepts of the significance of circulating mRNA, may be a useful tool to detect circulating thyroid cancer cells.
authors.affiliation: Institute of Clinical Chemistry, Hannover Medical School, Hannover, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Wehmeier
authors.forename: Thorsten
authors.initials: T
authors.lastname: Petrich
authors.forename: Korbinian
authors.initials: K
authors.lastname: Brand
authors.forename: Ralf
authors.initials: R
authors.lastname: Lichtinghagen
authors.forename: Eric
authors.initials: E
authors.lastname: Hesse
mesh_terms: D000328:Adult; D000368:Aged; D002291:Carcinoma, Papillary / Q000097:blood*; D005260:Female; D005353:Fibronectins / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood*; D013972:Thyrotropin / Q000097:blood*
chemical_list: D005353:Fibronectins; D012333:RNA, Messenger; C121542:oncofetal fibronectin; D013972:Thyrotropin